F9675
Anti-FLIPL C-Terminal antibody produced in rabbit
~0.5 mg/mL, IgG fraction of antiserum, buffered aqueous solution
别名:
Anti-CASHα
登录 查看组织和合同定价。
选择尺寸
关于此项目
Conjugate:
unconjugated
Clone:
polyclonal
Application:
ELISA, ICC, WB
Citations:
11
biological source
rabbit
conjugate
unconjugated
antibody form
IgG fraction of antiserum
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
mol wt
antigen 53 kDa
species reactivity
mouse
concentration
~0.5 mg/mL
technique(s)
ELISA: suitable, immunocytochemistry: suitable, western blot: suitable
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Quality Level
Gene Information
mouse ... Cflar(12633)
General description
In human Viral FLICE-inhibitory proteins (v-FLIPs) is identified as c-FLIP. It is composed of two death effector domains which have structural resemblance with the N-terminal half of caspase-8 and a caspase-like domain. It exist as multiple splice variants: FLIP α, β, γ, δ. Along with splice variants, it has two endogenous forms of the protein c-FLIPlong and c-FLIPshort.
Immunogen
synthetic peptide corresponding to amino acids 449-465 of the C-terminal region of mouse FLIPL.
Application
Anti-FLIPL C-Terminal antibody is suitable for western blot at 1-2 μg/mL. Antibody can also be used for immunocytochemistry starting at 5 μg/mL.
Biochem/physiol Actions
C-FLIP plays an important role in apoptosis signaling pathways. It acts as proapoptotic molecule or as an anti-apoptotic molecule. It has been reported that c-FLIP can interact with both FADD and caspase-8. It prevents caspase-8 recruitment and processing through DED-DED (death effector domain) interaction followed by CD95-induced apoptosis.
The antibody does not react with short form, FLIPS.
Physical form
Solution in 0.01 M phosphate buffered saline containing 0.02% sodium azide.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
未找到合适的产品？
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
法规信息
新产品
此项目有
M Thome et al.
Nature, 386(6624), 517-521 (1997-04-03)
Viruses have evolved many distinct strategies to avoid the host's apoptotic response. Here we describe a new family of viral inhibitors (v-FLIPs) which interfere with apoptosis signalled through death receptors and which are present in several gamma-herpesviruses (including Kaposi's-sarcoma-associated human
Apoptosis. Placing death under control.
D Wallach
Nature, 388(6638), 123-123 (1997-07-10)
S Hu et al.
The Journal of biological chemistry, 272(15), 9621-9624 (1997-04-11)
Molluscum contagiosum virus proteins MC159 and MC160 and the equine herpesvirus 2 protein E8 share substantial homology to the death effector domain present in the adaptor molecule Fas-associated death domain protein (FADD) and the initiating death protease FADD-like interleukin-1beta-converting enzyme
D M Rasper et al.
Cell death and differentiation, 5(4), 271-288 (1999-04-14)
Apoptotic cell suicide initiated by ligation of CD95 (Fas/APO-1) occurs through recruitment, oligomerization and autocatalytic activation of the cysteine protease, caspase-8 (MACH, FLICE, Mch5). An endogenous mammalian regulator of this process, named Usurpin, has been identified (aliases for Usurpin include
Y V Goltsev et al.
The Journal of biological chemistry, 272(32), 19641-19644 (1997-08-08)
CASP-8 and CASP-10, members of a cysteine protease family that participates in apoptosis, interact with MORT1/FADD, an adapter protein in the CD120a (p55 tumor necrosis factor receptor), and CD95 (Fas/Apo-1) death-inducing signaling pathways, through a shared N-terminal sequence motif, the
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持